clinical trial · NCT04962867
NCCH2006/MK010 Trial (FORTUNE Trial)
National Cancer Center, Japan·phase2·recruiting·n = 75
Advanced or Recurrent Solid TumorsFGFR Gene AlterationsE7090
brief summary
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
started
Jun 15, 2021
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Oct 3, 2025
official title
Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol